Connect with us

Business

Illumina Wins Case Against FTC on Grail Acquisition

An administrative legislation decide has dominated in favor of Illumina in its $7.1 billion acquisition of cancer-testing developer Grail Inc., dealing a defeat to the Federal Trade Commission’s efforts to unwind the deal on antitrust grounds, the corporate mentioned.

Illumina mentioned the decide rejected the FTC’s place that the deal would harm competitors out there for multicancer early-detection assessments.

Related Topics:Acquisition acquisitions Acquisitions/Mergers Acquisitions/Mergers/Shareholdings Anti-Competition Issues Biotechnology Business C&E Executive News Filter C&E Industry News Filter Cancer Case Content Types corporate Corporate Actions corporate crime Corporate Crime/Legal Action Corporate/Industrial News crime Crime/Legal Action Factiva Filters Federal Trade Commission FTC general news genomics Grail Health healthcare Healthcare/Life Sciences Illumina ILMN industrial news legal action life sciences Medical Conditions mergers Ownership Changes political Political/General News shareholdings SYND wins WSJ-PRO-WSJ.com

Campbell Soup’s Profit Slides as Costs Rise and Shoppers Rethink Spending

Ukraine Decries TotalEnergies’ Russia Dividend as ‘Blood Money’

Continue Reading

Click to comment

Leave a Reply
Cancel reply

Technology8 months ago

Elon Musk’s affordable internet service Starlink debuts in Japan

Travel8 months ago

Travel agency services market to reach USD 407.7 Bn in 2022

Sports8 months ago

Cam Rising gives No. 20 Utah the lift it needs to stun No. 7 USC

Business8 months ago

Toyota Starts Plant in Junta-Led Myanmar Making 1 to 2 Cars a Day

Fashion6 months ago

US’ Cult&Rain launches metaverse store & 250 core collection sneakers

Entertainment9 months ago

Dancing With the Stars 2022 Cast Revealed

Entertainment9 months ago

Blake Lively and Ryan Reynolds’s Relationship Timeline

World12 months ago

U.K. Economy Shrinks for Second Month as Outlook Dims